Navigation Links
FDA Approves Phase I Clinical Trial of Topaz Pharmaceuticals' New Head Lice Treatment

Topaz Pharmaceuticals LLC, a pharmaceutical company dedicated to the health and well being of children, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug application; allowing Topaz to begin clinical trials of the company's topical solution for the treatment of head lice.

The Topaz product is designed to give healthcare professionals a new choice for the treatment of head lice infestations - it will provide a naturally derived treatment that is lethal to lice and nits, yet safe to children and adults. Between 6 and 12 million children are affected by head lice in the United States each year. In many cases, the children with head lice are dismissed from school and not allowed to return until they are declared "lice free" -- impacting parents and children alike.

"This IND approval and the entry of our first subjects into clinical trials bring us closer to a significant milestone in the treatment of head lice," said Nick Spring, Topaz Pharmaceuticals president and chief executive officer.

"Current treatments on the market are either becoming less effective because of lice resistance or contain potentially hazardous substances. We remain confident and optimistic that the Topaz solution will be proven safe and effective in subsequent trials, and will eventually help alleviate the frustration, inconvenience and social stigma associated with head lice."

Topaz Pharmaceuticals LLC is a start-up company, which initially benefited from support provided by the Ben Franklin Technology Partners of Southeast Pennsylvania, who develops and markets pediatric medicines.

The company expects to develop additional indications covering other parasitic insects affecting human health. Topaz Pharmaceuticals is developing a completely novel and kid friendly formulation of a naturally derived, quick acting ingredient which is lethal to head and body lice.


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 26, 2016 ... value-based care operating models within the health care industry ... greater financial efficiency , Deloitte offers a suite ... key business issues impacting efficient cost optimization: labor resource ... , These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
Breaking Medicine Technology: